1.01

3.81% -0.04

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $1.01, with a volume of 10,926. It is down -3.81% in the last 24 hours and up +6.32% over the past month. Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Previous Close:

$1.05

Open:

$1.03

24h Volume:

10,926

Relative Volume:

0.26

Market Cap:

$4.02M

Revenue:

Net Income/Loss:

$-9.87M

P/E Ratio:

-0.0256

EPS:

-39.4678

Net Cash Flow:

$-8.76M

1W Performance:

-8.18%

1M Performance:

+6.32%

6M Performance:

-23.48%

1Y Performance:

-90.85%

1-Day Range:

$1.00

$1.03

1-Week Range:

$0.91

$1.10

52-Week Range:

$0.875

$11.60

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1086)

Industry

Biotechnology (605)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	1.01	4.26M	0	-9.87M	-8.76M	-39.47
VRTX Vertex Pharmaceuticals Inc	541.97	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.93	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,022.73	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	141.37	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.51	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Revelation Biosciences Inc Stock (REVB) Latest News

Aug 20, 2026

Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 20, 2026

Aug 19, 2026

Enterprise value to EBIT forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 19, 2026

Enterprise value to revenue forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView

Aug 19, 2026

Revelation Biosciences Grants Performance-Based Restricted Stock to CEO and CFO - Minichart

Aug 19, 2026

Form 8K Revelation Biosciences Inc For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026

Revelation Biosciences grants restricted stock awards to CEO and CFO - Investing.com

Aug 19, 2026

Revelation Biosciences Grants Performance-Based Executive Stock Awards - TipRanks

Aug 19, 2026

Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView

Aug 19, 2026

Revelation Biosciences (REVB) ties CEO, CFO pay to $30–120M cap tests - Stock Titan

Aug 19, 2026

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study - BioSpace

Aug 19, 2026

Revelation Biosciences selects CRO for phase 2/3 AKI study By Investing.com - Investing.com Canada

Aug 19, 2026

Revelation Biosciences selects CRO for phase 2/3 AKI study - Investing.com

Aug 19, 2026

Revelation Biosciences Selects Avance Clinical As Cro For Phase 2/3 Titan Study - TradingView

Aug 19, 2026

Aug 18, 2026

Revelation Biosciences (REVB) CFO gifts 416K shares - Stock Titan

Aug 18, 2026

Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan

Aug 18, 2026

Revelation Biosciences (NASDAQ: REVB) details insider trade - Stock Titan

Aug 18, 2026

Revelation Biosciences (REVB) insider logs stock trade in company shares - Stock Titan

Aug 18, 2026

Aug 14, 2026

Armistice Capital (REVB) discloses 4.99% Revelation Biosciences stake via Master Fund - Stock Titan

Aug 14, 2026

Aug 12, 2026

REVB Q2 2026 Earnings: Loss per Share Misses Consensus as Pre-Revenue Pipeline AdvancesCFO Commentary Report - Vinanet

Aug 12, 2026

Aug 08, 2026

Price to book forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView

Aug 08, 2026

Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView

Aug 08, 2026

Aug 07, 2026